Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590886 | 0.85 | NPY5R (0.55) | MAPTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL4078210 | 0.82 | MAPT (0.60) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL28588005 | 0.79 | MAPT (0.74) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL14468806 | 0.77 | MAPT (0.77) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL9251705 | 0.77 | RAB9A (0.53) | MAPTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL2255388 | 0.77 | MAPT (0.60) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL8171460 | 0.76 | MAPT (0.74) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL13685439 | 0.74 | RAB9A (0.57) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL3610890 | 0.73 | MAPT (0.64) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL14046024 | 0.72 | MAPT (0.52) | MAPTALDH1A1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652018-B2 | Imidazolidin-2-one derivatives useful as PR modulators | WYETH LLC (US) | 2010-01-26 | — | — | US | disclosed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021309-A1 | IMIDAZOLIDIN-2-ONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | PKD1, SHBG, NPY4R | MAPT 1647/4885ALDH1A1 3170/4885MEN1 30/4885 |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | MC2R, NPY1R, PRLHR | MAPT 1550/4885ALDH1A1 3334/4885MEN1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.